These results are in accordance with the theoretical anticancer effects of metformin, which are divided into direct effects, reducing the energy consumption of cancer cells by inhibiting mitochondrial respiratory chain complex I, and indirect effects, reducing fasting plasma insulin levels [37,38]. The gene discussed is INS; the disease is cancer.